Improving people’s quality of life
through innovative,
sustainable, and effective pain relief
through innovative,
sustainable, and effective pain relief
Innovation in pain relief
PharmNovo is a Swedish pharma company based in Medicon Village, Lund. PharmNovo has developed a novel compound portfolio based on a new type of selective delta opioid receptor agonists (DORAs), intended to provide effective neuropathic pain relief without the adverse side effects of conventional opioids. The lead candidate, PN6047, is currently in the final stages of phase I studies and PharmNovo is preparing for phase 2 studies with PN6047 in chronic neuropathic pain and potentially other diseases of the nervous system.
Read more
PN6047 is a unique substance based on research by PharmNovo’s founder Bengt von Mentzer. It is shown to be potent, safe, and effective and does not affect the receptors usually known to cause addiction to conventional opioids. It also lacks the usual unwanted side effects associated with other non-selective opioids. PN6047 will shortly be entering phase II proof-of-concept studies.
Read moreNeuropathic pain affects up to ten percent of the population in Europe and the United States, but the treatment of neuropathic pain is still a clearly unmet medical need. To date, there is no pain relief offered to these patients that is not associated with potentially severe side effects.
Read more
.jpeg)
PharmNovo will soon initiate a phase II proof of concept clinical study of the drug candidate PN6047 to show its effect on neuropathic pain conditions.
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read morePharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read morePharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more
